The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2026, according to Statista. The oncology segment alone is expected to generate $232 billion in sales this year.

The investment bank said many companies faced thesis-changing Phase 3 readouts this year, with outcomes that could materially reshape valuations regardless of the broader macro backdrop. But UBS also ...

On January 8, Michael Yee, global head of biotech research at UBS, appeared on CNBC’s ‘Squawk on the Street’ to discuss his ...

What Happened? Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) fell 5.3% in the afternoon session ...

Abivax ( ABVX +0.26%), a France-based biotech, saw its shares skyrocket by more than 1,740% last year after it made ...

Novo Nordisk oral Wegovy records 3,071 prescriptions in four days. Shares jump 6.5% as Eli Lilly oral weight loss drug awaits ...

The recent news of Novo Nordisk’s nearly 10% stock decline – currently -6.6% – following disappointing Alzheimer’s trial results for its Ozempic pill highlights the volatility in pharmaceutical stocks ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming ...

Recursion Pharmaceuticals has reported updated data from its ELUCIDATE & TUPELO trials, but the stock has failed to mount a ...

Entertainment Holding Corp. (Nasdaq:AENT) and Processa Pharmaceuticals, Inc. (Nasdaq:PCSA) on the RedChip Small Stocks, Big ...